Jan. 6, 2022

Immatics: Engineering the Right T Cell Receptor for Shared Tumor-Associated Targets

Immatics: Engineering the Right T Cell Receptor for Shared Tumor-Associated Targets
Spotify podcast player badge
Apple Podcasts podcast player badge
Pandora podcast player badge
RSS Feed podcast player badge
Spotify podcast player icon Apple Podcasts podcast player icon Pandora podcast player icon RSS Feed podcast player icon

Harpreet co-founded Immatics in 2000 to translate pioneering scientific discoveries in immunology into highly innovative immunotherapies to impact the lives of cancer patients.